[Nature Sub-Journal] After this treatment of pancreatic cancer mice, the survival rate is significantly improved, and the spread of cancer is also reduced!

This article is converted Medicine original, reproduced please indicate the source Author: Yun Introduction: Recently, researchers found that mice high levels of integrin β5 were iRGD chemotherapy, the survival rate of pancreatic ductal adenocarcinoma in mice significantly improved cancer The diffusion rate is also reduced! In the United States, people die of pancreatic cancer every 12 minutes.

The disease is usually diagnosed at an advanced stage, spreads rapidly, and the five-year survival rate is about 10%.

Although the disease can be treated with radiotherapy, surgery, and chemotherapy, it can develop drug resistance.

The pancreas is a large gland located behind the stomach.
It produces enzymes that help digestion and hormones that regulate blood sugar levels.

Pancreatic ductal adenocarcinoma (PDAC) is a subtype of pancreatic cancer, and its high degree of drug resistance is due in part to the hard-shelled outer layer surrounding the tumor.

Recently, researchers have revealed how a tumor-targeting peptide called iRGD sneaks into the outside of the tumor and uses fibrous tissue as a channel to sneak into the tumor and kill tumor cells.

The research was published in the journal Nature Communications under the title "Tumor-penetrating therapy for β5 integrin-rich pancreas cancer".

Researchers from the University of California, San Diego School of Medicine and Morse Cancer Center, in collaboration with the Sanford Burnham Prebis Institute for Medical Discovery and Columbia University, demonstrated a new wear that was tested in an animal model Penetrating tumor therapy can enhance the effect of chemotherapy, reduce cancer metastasis rate, and improve survival rate.

"This type of tumor is composed of dense fibrous tissue, which prevents drugs from trying to pass.

So it is challenging to treat.
Many drugs can reach the tumor's blood vessels, but they cannot penetrate deep into the tissue, which increases the difficulty of treatment."The first author of the study, Dr.
Tatiana Hurtado de Mendoza, an assistant project scientist at the University of California San Diego School of Medicine and Morse Cancer Center, said, "Our study found that iRGD that penetrates tumors can use this fiber network to transfer chemotherapy drugs Transported to the inside of the tumor and exerts a better effect.

"The research team examined the microenvironment of PDAC tumors in mouse models.

They found that after targeting tumor blood vessels, iRGD binds to high levels of integrin β5 (a protein produced by cancer-associated fibroblasts (CAF)) , Can produce a fibrous covering that protects tumors.

"We were able to replicate human diseases in our mouse model, and found that when mice with high levels of integrin β5 were subjected to iRGD chemotherapy, the survival rate was significantly improved, and cancer The rate of spread to other organs is also reduced.

Compared with chemotherapy alone, this may be a powerful treatment strategy for aggressive pancreatic cancer.

"The co-author of the study, Professor of Surgery at the University of California San Diego School of Medicine and Dean of the University of California San Diego, said Andrew Lowy.

This finding is also exciting because the iRGD treatment did not produce any other side effects, which is a treatment for patients.
The
researchers said that the next step will be a nationwide human clinical trial, which is estimated to be completed within a year.

Lowy said: "We believe that this study will enable many cancer patients to benefit from the combination therapy of iRGD.
.

”Reference materials: [1] https://medicalxpress.
com/news/2021-03-therapy-hard-layer-pancreatic-cancer.
html [2] https:// -21858-1 details